Last mentioned: 5h ago
Deal Termination
Alcon and LENSAR announce the end of the merger agreement due to FTC opposition.
2026 Strategic Focus
Strategic focus shifts toward AI-integrated ophthalmic surgical suites for the 2026 fiscal year.
Q4 2025 Earnings Report
Alcon reports Q4 2025 earnings, beating analyst expectations in key segments.
FTC Investigation
The FTC intensifies its review of the merger, focusing on the ophthalmic laser market.
Merger Agreement
Alcon and LENSAR enter into a definitive agreement for Alcon to acquire LENSAR.
Digital Health Expansion
Company announces expansion of its digital health platform for surgical planning.
Global ATIOL Rollout
Alcon begins global rollout of its latest advanced technology intraocular lens (ATIOL).
Alcon has officially terminated its merger agreement with LENSAR, a leader in femtosecond laser technology, citing insurmountable opposition from the Federal Trade Commission (FTC). The collapse of the deal highlights increasing regulatory scrutiny over consolidation within the specialized medical device and ophthalmic surgery sectors.
Alcon reported strong Q4 2025 results, highlighting robust demand in surgical equipment and vision care products. The company's performance signals a steady recovery in elective procedures and a growing market for advanced ophthalmic technologies, contrasting with volatility in other industrial sectors.
Alcon reported a Q4 core EPS of $0.78, narrowly missing the FactSet consensus of $0.79. While the miss was marginal, it highlights the ongoing pressure on medical device margins and the defensive posture of the healthcare sector compared to industrial peers.